Imperial College London

DrCharlotteVrinten

Business School

Research Associate
 
 
 
//

Contact

 

c.vrinten Website

 
 
//

Location

 

Business School BuildingSouth Kensington Campus

//

Summary

 

Summary

Charlotte is a Research Associate on the Rare2030 project and joined Imperial College Business School in 2019.  The aim of the Rare2030 project, which is co-funded by the European Union Pilot Projects and Preparatory Actions Programme, is to propose policy recommendations to guide future European policy on rare diseases by using a participatory foresight approach and additional innovative consensus building methods.  As part of this project, Charlotte investigates the R&D pipeline and the successful market launch of orphan drugs.  

Charlotte completed her PhD in Medicine on n-of-one trials for rare diseases at VU University in Amsterdam, using rare neuromuscular diseases as a case study.  Her dissertation examined the contribution that n-of-one trials can make to the creation of an evidence base for treatments for patients with rare diseases.  In addition to conducting two clinical trials using the n-of-one methodology, she also examined the acceptability of evidence from series of n-of-one trials to healthcare regulators and HTA agencies (i.e. the Dutch National Health Care Institute and the Dutch national competent authority for market approval of medicines, the Medicines Evaluation Board).

Before joining Imperial College, Charlotte worked as a Research Psychologist at the Department of Behavioural Science and Health at University College London. There, she examined the prevalence and sociodemographic distribution of cancer fear in the general population, and its association with uptake of cancer screening.  Charlotte holds degrees in Medicine (PhD), Psychology (BSc), and Philosophy (BA) and is an Associate Fellow of the Higher Education Academy (AFHEA).

Publications

Journals

Heard J-M, Vrinten C, Schlander M, et al., 2020, Availability, accessibility and delivery to patients of the 28 orphan medicines approved by the European Medicine Agency for hereditary metabolic diseases in the MetabERN network, Orphanet Journal of Rare Diseases, Vol:15, ISSN:1750-1172

Vrinten C, Stoffel S, Dodd RH, et al., 2019, Cancer worry frequency vs. intensity and self-reported colorectal cancer screening uptake: A population-based study., Journal of Medical Screening, Vol:26, ISSN:0969-1413, Pages:169-178

Vrinten C, Gallagher A, Waller J, et al., 2019, Cancer stigma and cancer screening attendance: a population based survey in England, Bmc Cancer, Vol:19

Vrinten C, Gallagher A, Waller J, et al., 2019, Cancer stigma and cancer screening attendance: a population based survey in England., Bmc Cancer, Vol:19

More Publications